Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial
Laura A Young, John B Buse, Mark A Weaver, Maihan B Vu, C Madeline Mitchell, Tamara Blakeney, Kimberlea Grimm, Jennifer Rees, Franklin Niblock, Katrina E Donahue, Monitor Trial Group, Laura A Young, John B Buse, Mark A Weaver, Maihan B Vu, C Madeline Mitchell, Tamara Blakeney, Kimberlea Grimm, Jennifer Rees, Franklin Niblock, Katrina E Donahue, Monitor Trial Group
Abstract
Importance: The value of self-monitoring of blood glucose (SMBG) levels in patients with non-insulin-treated type 2 diabetes has been debated.
Objective: To compare 3 approaches of SMBG for effects on hemoglobin A1c levels and health-related quality of life (HRQOL) among people with non-insulin-treated type 2 diabetes in primary care practice.
Design, setting, and participants: The Monitor Trial study was a pragmatic, open-label randomized trial conducted in 15 primary care practices in central North Carolina. Participants were randomized between January 2014 and July 2015. Eligible patients with type 2 non-insulin-treated diabetes were: older than 30 years, established with a primary care physician at a participating practice, had glycemic control (hemoglobin A1c) levels higher than 6.5% but lower than 9.5% within the 6 months preceding screening, as obtained from the electronic medical record, and willing to comply with the results of random assignment into a study group. Of the 1032 assessed for eligibility, 450 were randomized.
Interventions: No SMBG, once-daily SMBG, and once-daily SMBG with enhanced patient feedback including automatic tailored messages delivered via the meter.
Main outcomes and measures: Coprimary outcomes included hemoglobin A1c levels and HRQOL at 52 weeks.
Results: A total of 450 patients were randomized and 418 (92.9%) completed the final visit. There were no significant differences in hemoglobin A1c levels across all 3 groups (P = .74; estimated adjusted mean hemoglobin A1c difference, SMBG with messaging vs no SMBG, -0.09%; 95% CI, -0.31% to 0.14%; SMBG vs no SMBG, -0.05%; 95% CI, -0.27% to 0.17%). There were also no significant differences found in HRQOL. There were no notable differences in key adverse events including hypoglycemia frequency, health care utilization, or insulin initiation.
Conclusions and relevance: In patients with non-insulin-treated type 2 diabetes, we observed no clinically or statistically significant differences at 1 year in glycemic control or HRQOL between patients who performed SMBG compared with those who did not perform SMBG. The addition of this type of tailored feedback provided through messaging via a meter did not provide any advantage in glycemic control.
Trial registration: clinicaltrials.gov Identifier: NCT02033499.
Conflict of interest statement
Conflict of Interest Disclosures: Dr Young reports grants from Eli Lilly, grants from Bristol-Myers Squibb, grants and other from GI Dynamics, grants from PhaseBio, grants from Medtronic Minimed, grants from Sanofi, grants from Tolerex, grants from Halozyme, grants from Johnson & Johnson, grants from Andromeda, grants from Boehringer-Ingelheim, grants from GlaxoSmithKline, grants from Intarcia Therapeutics, grants from Lexicon, grants from Scion NeuroStim, grants from Orexigen, grants from Takeda, grants from Theracos, grants from Novo Nordisk, other from Dexcom, outside the submitted work; she is a member of the planning committee for Taking Control of Your Diabetes; and UNC has licensed its interest in copyright works to Telcare of a glucose messaging and treatment algorithm for the purposes of commercialization. Dr Buse reports grants, nonfinancial support, and other from Eli Lilly, grants, nonfinancial support, and other from Bristol-Myers Squibb, grants, nonfinancial support, and other from GI Dynamics, nonfinancial support and other from Elcylex, grants, nonfinancial support, and other from Merck, nonfinancial support and other from Metavention, nonfinancial support and other from vTv Pharma, grants, personal fees, nonfinancial support, and other from PhaseBio, grants, nonfinancial support, and other from AstraZeneca, nonfinancial support and other from Dance Biopharm, nonfinancial support and other from Quest, grants from Medtronic Minimed, grants, nonfinancial support, and other from Sanofi, grants from Tolerex, grants from Osiris, grants from Halozyme, grants from Johnson & Johnson, grants from Andromeda, grants from Boehringer-Ingelheim, grants from GlaxoSmithKline, grants from Astellas, grants from MacroGenics, grants from Intarcia Therapeutics, grants, nonfinancial support, and other from Lexicon, grants from Scion NeuroStim, grants, nonfinancial support, and other from Orexigen, grants, nonfinancial support, and other from Takeda, nonfinancial support and other from Adocia, grants, nonfinancial support, and other from F. Hoffman LaRoche, grants from Theracos, grants, nonfinancial support, and other from Novo Nordisk outside the submitted work; and he is or has been a member of a variety of nonprofit boards: American Diabetes Association, DiabetesSisters, Taking Control of Your Diabetes, AstraZeneca Healthcare Foundation, Bristol-Myers Squib Together on Diabetes Foundation, the National Diabetes Education Program; and UNC has licensed its interest in copyright works to Telcare of a glucose messaging and treatment algorithm for the purposes of commercialization. Dr Donahue reports UNC has licensed its interest in copyright works to Telcare of a glucose messaging and treatment algorithm for the purposes of commercialization. No other disclosures are reported.
Figures
Source: PubMed